MacroGenics (MGNX) AI Stock Analysis

• Market Cap: $99.68M
• Dividend Yield: N/A
• Average Volume (3M): 1.04M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.11
• Revenue Growth: 255.31%
• EPS Growth: -141.39%
• Country: US
• Employees: 341
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.65
• Shares Outstanding: 63,090,324
• 10 Day Avg. Volume: 775,416
• 30 Day Avg. Volume: 1,041,511
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -0.37
• Enterprise Value/Revenue: -0.24
• Enterprise Value/Gross Profit: -0.27
• Enterprise Value/Ebitda: 0.78
• 1Y Price Target: $4.75
• Price Target Upside: 200.63% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

• Rating: 51 Neutral
• Price Target: $1.50 ▼(-5.06%Downside)

MacroGenics' overall stock score reflects a challenging financial position with profitability and liquidity concerns, offset by a positive corporate event boosting near-term cash flow. Technical indicators and valuation metrics are mixed, contributing to a moderate score.

Positive Factors

Pipeline Progress

MGNX continues to make progress across its broader pipeline, including the initiation of the Phase II LINNET study and the upcoming clinical update from the Phase II LORIKEET study.

Resource Allocation

The discontinuation of vobra duo is viewed positively as it allows the company to reallocate resources to programs with higher probability of success, including the second B7-H3 ADC program, MGC026.

Negative Factors

Development Risks

Risks include clinical setbacks with MGC026, lorigerlimab, MGC028, and MGC030, competitive landscape risks, partnership risks, and possible long-term dilution risk.

Financial Performance

MacroGenics reported a full-year 2024 net loss of $1.07 per share, slightly wider than the previous forecast of a net loss of $0.95 per share.

Price Target Revision

The 12-month price target has been lowered to $2 per share from the prior $4 per share.

MacroGenics Business Overview & Revenue Model

Company Description

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

How the Company Makes Money

MacroGenics generates revenue through a combination of product sales, collaborative agreements, and licensing arrangements. The company earns revenue from its strategic partnerships with larger pharmaceutical companies, which may include upfront payments, milestone payments, and royalties based on the successful development and commercialization of its therapeutic candidates. Additionally, MacroGenics may receive government grants and funding for specific research initiatives. The company's revenue is heavily reliant on the progress and commercialization of its pipeline products, as well as the success of its collaborative partnerships in advancing those products to market.

MacroGenics Financial Statement Overview

Summary

MacroGenics faces significant financial challenges, with profitability and liquidity being major concerns. Although the gross profit margin is strong, ongoing operational inefficiencies and negative cash flows highlight the need for improved cash flow management and operational performance.

Income Statement

MacroGenics has shown inconsistent revenue growth, with a significant increase in 2023 but a decline in 2024. The gross profit margin remains strong, but the company struggles with negative EBIT and net profit margins, indicating ongoing operational challenges and profitability issues.

Balance Sheet

The balance sheet reflects moderate stability with a manageable debt-to-equity ratio. However, the declining stockholders' equity and high liabilities suggest potential financial strain. The equity ratio is decreasing, indicating a reliance on debt financing.

Cash Flow

Cash flow analysis reveals negative free cash flow and operating cash flow, indicating liquidity challenges. The free cash flow to net income ratio is negative, highlighting the company's difficulty in converting earnings into cash flow.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	148.34M	57.19M	151.94M	75.64M	97.76M
Gross Profit	136.04M	48.97M	144.56M	72.99M	-95.44M
EBITDA	-57.37M	2.02M	-107.89M	-190.86M	-117.78M
Net Income	-66.97M	-9.06M	-120.02M	-190.86M	-117.78M
Balance Sheet
Total Assets	261.65M	298.42M	280.47M	335.25M	378.74M
Cash, Cash Equivalents and Short-Term Investments	201.67M	229.81M	154.35M	243.62M	272.53M
Total Debt	37.46M	33.97M	34.83M	25.47M	29.25M
Total Liabilities	145.60M	145.81M	138.46M	95.63M	82.86M
Stockholders Equity	116.06M	152.61M	142.01M	239.62M	295.88M
Cash Flow
Free Cash Flow	-72.08M	-79.97M	-90.58M	-150.03M	-117.80M
Operating Cash Flow	-68.37M	-78.20M	-86.96M	-143.83M	-111.90M
Investing Cash Flow	149.30M	-80.08M	70.72M	-36.61M	-7.79M
Financing Cash Flow	960.00K	150.36M	1.66M	122.78M	174.34M

MacroGenics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.58
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGNX, the sentiment is Neutral. The current price of 1.58 is above the 20-day moving average (MA) of 1.57, above the 50-day MA of 1.50, and below the 200-day MA of 2.40, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 51.94 is Neutral, neither overbought nor oversold. The STOCH value of 21.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MGNX.

MacroGenics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRBU	52 Neutral	$181.36M	―	-52.76%	―	-70.31%	-11.68%
Sector *	51 Neutral	$7.37B	0.33	-68.94%	2.37%	16.27%	0.42%
MGNX	51 Neutral	$99.68M	―	-60.25%	―	255.31%	-141.39%
VXRT	43 Neutral	$81.45M	―	-114.74%	―	433.43%	49.04%
PLRX	37 Underperform	$96.99M	―	-63.22%	―	-100.00%	-26.44%
TNYA	36 Underperform	$109.08M	―	-76.21%	―	―	23.55%
ELTX	30 Underperform	$159.65M	―	-744.59%	―	―	27.65%

MacroGenics Corporate Events

MacroGenics Enters Royalty Purchase Agreement with Sagard

On June 9, 2025, MacroGenics, Inc. entered into a Royalty Purchase Agreement with Sagard Healthcare Partners, selling its rights to receive royalties on global net sales of ZYNYZ (retifanlimab-dlwr) starting July 1, 2025. MacroGenics received a $70 million upfront payment, which extends its cash runway through the first half of 2027. Sagard will collect royalties until they reach $140 million, after which MacroGenics will resume collecting royalties. This agreement allows MacroGenics to retain other economic interests in ZYNYZ, including potential development and commercial milestones, while continuing to support global manufacturing needs.

The most recent analyst rating on (MGNX) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on MacroGenics stock, see the MGNX Stock Forecast page.

MacroGenics Holds Annual Stockholders Meeting on May 21

On May 21, 2025, MacroGenics, Inc. held its Annual Meeting of Stockholders, where approximately 82% of the company’s common stock was represented. During the meeting, stockholders elected four Class III directors for a three-year term, ratified the appointment of Ernst & Young LLP as the independent auditor for 2025, approved executive compensation, and amended the 2023 Equity Incentive Plan to increase available shares by 1,250,000. These decisions reflect the company’s ongoing governance and strategic planning efforts, potentially impacting its operational focus and shareholder value.

The most recent analyst rating on (MGNX) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on MacroGenics stock, see the MGNX Stock Forecast page.